Please use this identifier to cite or link to this item:
Title: Enhanced liver fibrosis score as a biomarker for vascular damage assessment in patients with takayasu arteritis—a pilot study
Authors: Stojanovic, Marijana
Raskovic Z.
Milivojevic V.
Miskovic, Rada
Soldatovic, Ivan
Sanja S.
Rankovic I.
Stanojević M.
Dragasevic N.
Krstić M.
Diamantopoulos A.
Issue Date: 2021
Abstract: Takayasu Arteritis (TA) is characterized by granulomatous panarteritis, vessel wall fibrosis, and irreversible vascular impairment. The aim of this study is to explore the usefulness of the Enhanced Liver Fibrosis score (ELF), procollagen-III aminoterminal propeptide (PIIINP), tissue inhibitor of matrix metalloproteinase-1 (TIMP-1), and hyaluronic acid (HA) in assessing vascular damage in TA patients. ELF, PIIINP, TIMP-1, and HA were measured in 24 TA patients, and the results were correlated with the clinical damage indexes (VDI and TADS), an imaging damage score (CARDS), and disease activity scores (NIH and ITAS2010). A mean ELF score 8.42 (±1.12) and values higher than 7.7 (cut-off for liver fibrosis) in 21/24 (87.5%) of patients were detected. The VDI and TADS correlated significantly to ELF (p < 0.01). Additionally, a strong association across ELF and CARDS (p < 0.0001), PIIINP and CARDS (p < 0.001), and HA and CARDS (p < 0.001) was observed. No correlations of the tested biomarkers with inflammatory parameters, NIH, and ITAS2010 scores were found. To our knowledge, this is the first study that suggests the association of the serum biomarkers PIIINP, HA, and ELF score with damage but not with disease activity in TA patients. The ELF score and PIIINP may be useful biomarkers reflecting an ongoing fibrotic process and quantifying vascular damage.
Type: article
DOI: 10.3390/jcdd8120187
SCOPUS: 2-s2.0-85121784584
Appears in Collections:Faculty of Medical Sciences, Kragujevac

Page views(s)




Files in This Item:
File Description SizeFormat 
10.3390-jcdd8120187.pdf269.89 kBAdobe PDFThumbnail

This item is licensed under a Creative Commons License Creative Commons